IL18 and melanoma: The introduction of secreted biologically responsive mature IL18 to enhanced the anti-tumor capacity of Pmel-1-specific T cells infused into melanoma B16F10 hormonal mice to secrete IFN-γ and express CD25, and reduced the aggregation of immune-suppressor cells in the TME, effectively prolonging the survival rate of the mice.